IN2014DN09347A - - Google Patents

Info

Publication number
IN2014DN09347A
IN2014DN09347A IN9347DEN2014A IN2014DN09347A IN 2014DN09347 A IN2014DN09347 A IN 2014DN09347A IN 9347DEN2014 A IN9347DEN2014 A IN 9347DEN2014A IN 2014DN09347 A IN2014DN09347 A IN 2014DN09347A
Authority
IN
India
Prior art keywords
compounds
disorders
substituents
useful
formula
Prior art date
Application number
Other languages
English (en)
Inventor
Stephen Deems Gabriel
Matthew Michael Hamilton
Yimin Qian
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48656033&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN09347(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2014DN09347A publication Critical patent/IN2014DN09347A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
IN9347DEN2014 2012-06-20 2013-06-17 IN2014DN09347A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661958P 2012-06-20 2012-06-20
PCT/EP2013/062458 WO2013189862A1 (fr) 2012-06-20 2013-06-17 Composés de pyrazole substitués utilisés comme antagonistes de lpar

Publications (1)

Publication Number Publication Date
IN2014DN09347A true IN2014DN09347A (fr) 2015-07-17

Family

ID=48656033

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9347DEN2014 IN2014DN09347A (fr) 2012-06-20 2013-06-17

Country Status (22)

Country Link
US (1) US20150259295A1 (fr)
EP (1) EP2864294A1 (fr)
JP (1) JP2015520201A (fr)
KR (1) KR20150011003A (fr)
CN (1) CN104411690A (fr)
AU (1) AU2013279510A1 (fr)
BR (1) BR112014031108A2 (fr)
CA (1) CA2869602A1 (fr)
CL (1) CL2014003242A1 (fr)
CO (1) CO7160077A2 (fr)
CR (1) CR20140516A (fr)
EA (1) EA201492283A1 (fr)
HK (1) HK1206341A1 (fr)
IL (1) IL236091A0 (fr)
IN (1) IN2014DN09347A (fr)
MA (1) MA37765A1 (fr)
MX (1) MX2014014105A (fr)
PE (1) PE20142445A1 (fr)
PH (1) PH12014502364A1 (fr)
SG (1) SG11201407229UA (fr)
UA (1) UA109867C2 (fr)
WO (1) WO2013189862A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG2014011555A (en) 2011-08-15 2014-08-28 Intermune Inc Lysophosphatidic acid receptor antagonists
SG10201803833WA (en) 2013-03-15 2018-06-28 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
MX370408B (es) 2014-06-27 2019-12-11 Ube Industries Sal de compuesto heterociclico sustituido con halogeno.
AU2018388482A1 (en) * 2017-12-19 2020-07-30 Bristol-Myers Squibb Company Pyrazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
KR20220101137A (ko) 2019-11-15 2022-07-19 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도
TW202344504A (zh) 2020-06-03 2023-11-16 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
AU2021282986B2 (en) 2020-06-03 2024-03-07 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
TWI818538B (zh) * 2021-05-11 2023-10-11 美商基利科學股份有限公司 Ｌｐａ受體拮抗劑及其用途
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1698335A4 (fr) * 2003-12-26 2007-08-01 Ono Pharmaceutical Co Agent pour prevenir et/ou de traiter des maladies faisant intervenir un recepteur de benzodiazepine mitochondrial
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
WO2011017350A2 (fr) * 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Composés en tant qu'antagonistes du récepteur de l'acide lysophosphatidique
BR112013014019A2 (pt) * 2010-12-07 2016-09-13 Amira Pharmaceuticals Inc antagonistas do receptor do ácido lisofosfatídico e seus usos
WO2012138648A1 (fr) * 2011-04-06 2012-10-11 Irm Llc Compositions et procédés pour la modulation de récepteurs au lpa
SG2014011555A (en) * 2011-08-15 2014-08-28 Intermune Inc Lysophosphatidic acid receptor antagonists

Also Published As

Publication number Publication date
KR20150011003A (ko) 2015-01-29
US20150259295A1 (en) 2015-09-17
CO7160077A2 (es) 2015-01-15
JP2015520201A (ja) 2015-07-16
MX2014014105A (es) 2015-03-05
CL2014003242A1 (es) 2015-03-20
EA201492283A1 (ru) 2015-04-30
IL236091A0 (en) 2015-02-01
CN104411690A (zh) 2015-03-11
SG11201407229UA (en) 2014-12-30
HK1206341A1 (en) 2016-01-08
UA109867C2 (ru) 2015-10-12
CR20140516A (es) 2014-12-01
PE20142445A1 (es) 2015-01-28
EP2864294A1 (fr) 2015-04-29
WO2013189862A1 (fr) 2013-12-27
CA2869602A1 (fr) 2013-12-27
PH12014502364A1 (en) 2015-01-12
AU2013279510A1 (en) 2014-10-16
BR112014031108A2 (pt) 2017-06-27
MA37765A1 (fr) 2017-04-28

Similar Documents

Publication Publication Date Title
IN2014DN09352A (fr)
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
IN2014DN09347A (fr)
WO2014179564A8 (fr) Inhibiteurs du ror-gamma à base de thiazolopyrrolidine
IN2014DN09434A (fr)
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
IN2014MN02598A (fr)
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
IN2015DN01119A (fr)
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
MX2016002794A (es) Compuestos antiproliferativos.
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
WO2014045162A8 (fr) Composés d'hexahydropyrano[3,4-d][1,3]thiazine-2-amine alkyl-substitués
WO2013004995A8 (fr) Composés pyrimidinones et leur utilisation
IN2014DN06869A (fr)
MX340574B (es) Imidazo pirazinas.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
WO2015002755A3 (fr) Composés pour le traitement du paludisme
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
WO2014160143A3 (fr) Composés d'isatine, compositions et procédés pour le traitement de maladies et de troubles dégénératifs
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions